Protara Therapeutics Inc
TARA3.085USD
+0.025+0.82%
交易中 （美東）報價延遲15分鐘
119.01M總市值
虧損本益比TTM
關於 Protara Therapeutics Inc 公司
Protara Therapeutics, Inc. 是一家臨牀階段的生物技術公司，致力於爲癌症和罕見疾病患者開發變革性療法。該公司的產品組合包括其主要候選藥物 TARA-002，這是一種正在開發的用於治療非肌層浸潤性膀胱癌 (NMIBC) 和淋巴畸形 (LM) 的試驗性細胞療法。該公司正在對 TARA-002 進行一項正在進行的 II 期試驗，該試驗針對對卡介苗 (BCG) 治療無反應或未接受過治療的原位癌 (CIS) NMIBC 患者，以及一項 II 期試驗，該試驗針對患有 LM 的兒科患者。此外，該公司正在開發靜脈注射氯化膽鹼，這是一種試驗性磷脂底物替代品，適用於接受腸外營養且無法通過口服或腸內途徑滿足膽鹼需求的患者。
公司簡介
公司代碼TARA
公司名稱Protara Therapeutics Inc
上市日期Oct 22, 2014
CEOMr. Jesse Shefferman
員工數量28
證券類型Ordinary Share
年結日Oct 22
公司地址345 Park Avenue South
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編10010
電話16468440337
網址https://protaratx.com/
公司代碼TARA
上市日期Oct 22, 2014
CEOMr. Jesse Shefferman
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Mr. Gregory P. Sargen
Mr. Gregory P. Sargen
Independent Director
Independent Director
31.00K
--
Dr. Michael Edward (Mike) Solomon, Ph.D.
Dr. Michael Edward (Mike) Solomon, Ph.D.
Independent Director
Independent Director
26.50K
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Chief Financial Officer
Chief Financial Officer
4.27K
-79.09%
Ms. Justine O'Malley
Ms. Justine O'Malley
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
收入明細
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
持股股東
持股股東
佔比
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
21.94%
Hedge Fund
20.37%
Investment Advisor
15.94%
Venture Capital
13.71%
Individual Investor
2.88%
Research Firm
2.69%
Pension Fund
0.19%
Bank and Trust
0.10%
Other
22.18%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
113
30.02M
77.80%
-5.36M
2025Q1
109
30.14M
79.11%
-5.49M
2024Q4
103
31.00M
91.11%
+17.03M
2024Q3
78
11.90M
57.00%
-1.22M
2024Q2
78
11.87M
56.87%
+435.17K
2024Q1
73
5.94M
51.57%
-1.39M
2023Q4
74
5.63M
49.24%
-1.76M
2023Q3
82
6.95M
61.22%
-1.14M
2023Q2
92
7.24M
64.00%
-2.26M
2023Q1
120
7.75M
68.57%
-3.28M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
3.79M
9.82%
--
--
Mar 31, 2025
RA Capital Management, LP
3.40M
8.81%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.74M
4.52%
+64.04K
+3.81%
Mar 31, 2025
Opaleye Management Inc.
1.73M
4.48%
-95.00K
-5.21%
Mar 31, 2025
Velan Capital Investment Management LP
1.67M
4.32%
+88.80K
+5.62%
Mar 31, 2025
The Vanguard Group, Inc.
1.60M
4.15%
+243.34K
+17.90%
Mar 31, 2025
Sio Capital Management, LLC
1.51M
3.92%
+76.80K
+5.34%
Mar 31, 2025
Integral Health Asset Management, LLC
1.40M
3.63%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
1.28M
3.32%
--
--
Mar 31, 2025
StemPoint Capital LP
1.19M
3.09%
+858.18K
+258.18%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
